No announcement yet.

Stem Cell Transplantation for Autoimmune Disease—Is It Now Ready for Prime Time?

  • Filter
  • Time
  • Show
Clear All
new posts

  • Stem Cell Transplantation for Autoimmune Disease—Is It Now Ready for Prime Time?

    To get the answer, one will have to purchase the article, but here is the abstract. - Dave

    Biology of Blood and Marrow Transplantation
    Volume 18, Issue 1, Supplement , Pages S177-S183, January 2012

    Autologous Hematopoietic Stem Cell Transplantation for Autoimmune Disease—Is It Now Ready for Prime Time?

    Harold L. Atkins, Paolo A. Muraro, Jacob M. van Laar, Steven Z. Pavletic


    Current systemic therapies are rarely curative for patients with severe life-threatening forms of autoimmune disease (AID). During the past 15 years, autologous hematopoietic stem cell transplantation (HCT) has been demonstrated to cure some patients with severe AID refractory to all other available therapies, and thus AID has become an emerging indication for cell therapy. The sustained clinical effects after autologous HCT are better explained by qualitative change in the reconstituted immune repertoire rather than transient depletion of immune cells. Since 1996, more than 1300 AID patients have been registered by the European Group for Blood and Marrow Transplantion (EBMT) and almost 500 patients by the Center for International Blood and Marrow Transplant Research (CIBMTR).

    Autologous HCT is most commonly performed for patients with multiple sclerosis (MS) or systemic sclerosis (SSc). Systemic lupus, Crohn’s disease, type I diabetes, and juvenile idiopathic arthritis are other common indications. Allogeneic transplants are still considered too toxic for use in AID, except for cases of immune cytopenia. Although biologic therapies have been effective at controlling the manifestations of the disease, they require continuous administration, thus raising questions about their increasing costs, morbidity, and mortality related to prolonged therapy. Perhaps it is a reasonable time to ask, “Is autologous HCT for severe AID now ready for prime time?” Yet, the paucity of controlled studies, the short-term toxicities, and the upcoming availability of second-generation biologic and targeted immunotherapies argues that perhaps HCT for AID should be still limited to clinical trials. In this article, we focus on the results of autologous HCT for MS and SSc because these are the two most commonly transplanted diseases. The promising data that is emerging may establish these diseases as standard indications for HCT.
    Dave Bexfield